1. Home
  2. PONO vs IPHA Comparison

PONO vs IPHA Comparison

Compare PONO & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PONO

Pono Capital Four Inc. Class A Ordinary Shares

N/A

Current Price

$10.04

Market Cap

174.2M

Sector

Finance

ML Signal

N/A

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.50

Market Cap

165.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PONO
IPHA
Founded
2026
1999
Country
Cayman Islands
France
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
174.2M
165.3M
IPO Year
2026
2014

Fundamental Metrics

Financial Performance
Metric
PONO
IPHA
Price
$10.04
$1.50
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $6.67
AVG Volume (30 Days)
★ 62.0K
33.5K
Earning Date
11-12-2026
09-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$390.56
Revenue Next Year
N/A
$143.06
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.95
$1.17
52 Week High
$10.09
$2.71

Technical Indicators

Market Signals
Indicator
PONO
IPHA
Relative Strength Index (RSI) 61.16 41.16
Support Level $10.02 $1.36
Resistance Level $10.09 $1.57
Average True Range (ATR) 0.01 0.08
MACD 0.00 0.02
Stochastic Oscillator 37.50 33.33

Price Performance

Historical Comparison
PONO
IPHA

About PONO Pono Capital Four Inc. Class A Ordinary Shares

Pono Capital Four Inc is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: